To realize a world in which people to actively select means
to achieve health and satisfaction for mind & body
Mediford Corporation was established on November 1, 2023 by combining the drug development support businesses of LSIM Safety Institute Corporation and LSI Medience Corporation.
Mediford Corporation originates in two business fields.
One is non-clinical study services originally provided by LSIM Safety Institute Corporation such as safety and efficacy evaluations of pharmaceuticals, regenerative medicinal products, etc., in compliance with Good Laboratory Practice (GLP). The other is, "Bioanalysis Services" that utilize advanced analytical technologies such as biomarker analysis and drug concentration measurement, along with "Central Laboratory Services" covering the whole processes related to clinical trials originally provided by the drug development segment of LSI Medience Corporation.
mediford responds to various needs for new modalities in pharmaceutical R&D by fusing knowledge and technology accumulated in both businesses. We will make fit-for-purpose proposals by selecting suitable analytical technologies with a comprehensive perspective from wide range of technologies covering from non-clinical to clinical phase studies.
As a member of the PHC Group, mediford will enhance its services and develop novel technologies, and expand the services to pharmaceutical companies and analytical laboratories worldwide to be in line with globalization drug development. mediford will expand partnerships with pharmaceutical companies, ventures and academia in cutting-edge scientific fields to contribute to advancement of new drugs and healthcare.
We contribute to people's health and comfortable life through our reliable quality and advanced testing technologies.
Mediford Corporation will accelerate your research and development with our highly reliable analytical services.
Mediford Corporation offers a variety of contract services from establishment and banking of PDX-derived cell lines to conducting pharmacological studies at the GLP-certified facilities of Kumamoto Laboratories. The PDX models are more predictive of clinical outcomes than conventional "cancer cell lines" and will be useful for your research and development purposes.
Mediford Corporation provides various contract services using clinical isolates (PDC: Patient-Derived Cell) established at the National Cancer Center.
We provide a wide range of services in the development of regenerative medicine products from consulting to medical writing for diseases that are difficult to treat with conventional methods. We support each stage of the development process up to submission of application for approval by providing contract services that meet a wide variety of research needs, including toxicity studies (GLP), efficacy and biodistribution studies (reliability standards), and medical writing at research facilities fully accredited by AAALAC.
Mass Spectrometry Imaging (MSI) is a molecular imaging technique in which target molecules are ionized on a tissue section, and the distribution of ions are determined with a mass spectrometer and visualized.
Mediford Corporation has a long track record of commissions for PBMC separations in clinical trials. We pick up blood samples from study sites, and highly skilled researchers conduct the PBMC isolation process at the GLP laboratory located in Itabashi, Tokyo.
In recent years, next generation pharmaceuticals have become more actively developed all over the world. Among them, nucleic acid pharmaceuticals have been on the market every year since 2016 and are typical novel modalities which are expected to be further development in the future. In drug development, evaluation of ‘drug metabolism and disposition’ is important, and quantitative analysis of drugs in biological samples is essential.